Zoznam klinických štúdií liekov - skúšajúci MUDr. Vladimír Hacek

1. Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients (2005 - 2006)

The primary aim was to investigate the long-term safety and tolerability of escitalopram (10 or 20 mg/day) treatment of elderly patients suffering from major depressive disorder. The secondary aim was to examine response to treatment, as measured by change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from study entry to each visit, using observed cases.

2. A randomised, 6-week, multicentre, open-label, rater-blinded parallel-group study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with treatment resistant depression (2008 - 2009)

Kód štúdie: D1443L00044, RUBY, 2008-000908-91 Žiadateľ: AstraZeneca AB, o.z., 811 08 Bratislava, Lazaretská 8

The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.

3. A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence (2009 - 2010); sponsored by H. Lundbeck A/S

This study evaluated the long-term efficacy and safety of nalmefene treatment in reducing alcohol consumption. We randomised (1:3) 675 alcohol-dependent patients ≥ 18 years of age to 52 weeks of as-needed treatment with placebo or nalmefene 18 mg/day.